One way to develop prognostic and predictive tests in oncology is through the use of genomic biomarkers. And as more diagnostics companies are recognizing the potential benefits of this method, we’re seeing an increase in the number of companion diagnostic tests relying on gene-based biomarkers. Another reason for this continued trend towards personalized medicine is the continually decreasing costs of whole-genome sequencing.Read More
Scientists Prime The Immune System As A Powerful Cancer Weapon
Review of ASCO starting with the summary of a proof-of principle study presented by NCI answering the question if T-cells could be utilized to fight solid tumors.
Our immune systems can unmask tumours and cure cancer, experts say, calling immuno-oncology the biggest breakthrough in years
Review of cancer immunotherapy study results from several drug companies recently presented at ASCO conference including comments to the status of Immunotherapy by several oncology experts from pharmaceutical industry and academic research such as David Hafler (Yale University), Dr. Roy Baynes (senior vice-preseident of clinical research at Merck) and Michael Giordano (Head of Oncology at BMS).
Pharma vies to unleash immune system power on cancer
An overview of ongoing cancer immunotherapy trials and related achievements of the major drug companies chasing to get a share of the estimated enormous market potential of immuno-oncology drugs.
Nearly every day there seems to be exciting news or developments in the field of immunotherapy and immuno-oncology. Not only can you read all about immunotherapy research in leading scientific journals (1), but the mainstream media now reports on the latest immunotherapy clinical trial results from pharmaceutical companies.
But what exactly is immunotherapy and what technologies are needed to realize its full potential for the treatment of cancer? Throughout this whitepaper, Definiens will answerthose questions as well as provide insight into other commonly asked questions about immunotherapy:
- Why is it predicted that 60% of cancer treatments will be based on immunotherapy in the next 10 years?
- What are some of the more common approaches to immunotherapy today?
- What will be needed to accurately identify patients that will respond to immunotherapy treatment?
- How can knowing a patient’s immune status predict long-term treatment success?
- How is the use of Tissue Phenomics™ enabling effective clinical decision-making in oncology?
Download your copy of An Introduction To Immunotherapy And The Promise Of Tissue Phenomics™ to learn more.Read More
Dr. Rosenberg Discusses the Curative Potential of Cancer Immunotherapy
In this video, Dr. Steven A Rosenberg will introduce you to NCIs recently published developments describing how they used exomic sequencing to discover and isolate the immunogenic mutations to use in cancer immunotherapy.
Will Cancer Immunotherapy Open a New Era in the Treatment of Cancer?
You will learn in this video how Dr. George Coukos assesses the present and future of immuno-oncology highlighting the value and utilization of checkpoint inhibitors and cell-based therapeutics.
ITOC 2014: Toll Like Receptor 7 Agonists for Cancer Immunotherapy
Watch Dr. Stefan Enders describe two approaches that redirect the body’s own immune system to attack cancer. The first involves utilizing TLR7 receptors to activate NK cells to kill cancerous tumors. The second approach involves activating the immune system while down-regulating production of proteins that tumor cells need to survive.
Dr. Balar on Immunotherapy Treatment in Bladder Cancer
Immunotherapy has been used in treating bladder cancer for a while now. Learn from Dr. Arjun Balar as he discusses how the checkpoint inhibitors CTLA-4 and PD-1 are changing the landscape of immunotherapy for treatment of invasive bladder cancer.
Cancer Immunotherapy: Hot With Promise, Potential Breakthroughs
If there’s a science equivalent to the Oscars, or People magazine’s Sexiest Man Alive, this might be it: last year Cancer Immunotherapy – a technique that harnesses the body’s own immune system to fight cancer — was named Science magazine’s “breakthrough of the year.”
NIH study demonstrates that a new cancer immunotherapy method could be effective against a wide range of cancers
A new method for using immunotherapy to specifically attack tumor cells that have mutations unique to a patient’s cancer has been developed by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health. The researchers demonstrated that the human immune system can mount a response against mutant proteins expressed by cancers that arise in epithelial cells which can line the internal and external surfaces (such as the skin) of the body. These cells give rise to many types of common cancers, such as those that develop in the digestive tract, lung, pancreas, bladder and other areas of the body.
New Cancer Immunotherapy Aims Powerful T Cells Against Tumors
Deadly skin cancers in mice shrank in response to a new treatment that may complement other “immunotherapies” developed recently to boost the body’s own defenses against disease threats, according to a new study published by UC San Francisco researchers in the May 2014 edition of the Journal of Experimental Medicine.
Advances in Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
Despite recent developments in targeted therapies, the overall survival for metastatic NSCLC remains poor. The need for novel therapeutic options has led to the development of various new immunotherapeutic agents including anti-PD-1 and anti-PD-L1 antibodies, which appear to have a promising role in the treatment of the disease. Additionally, other immunotherapy options including CTLA-4 inhibitors and various vaccines are also currently being investigated as potential treatment options.